Patent classifications
C07D213/63
SHP2 inhibitors and uses thereof
Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows:
##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, A, W, L, R.sub.a, and G are defined herein:
and by Formula (II) as follows:
##STR00002##
wherein R.sup.1B, W.sub.B, L.sub.B, , and G.sub.B are defined herein.
BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX
Compounds and methods of using the same for treating conditions alleviated by SKI complex inhibition, viral replication inhibition, or interferon signaling inducement are provided.
Vicinal primary diamines associated with metal and/or free radical chelation motifs, and active against carbonyl and oxidative stress, and use thereof
The invention relates to compounds of Formula I: ##STR00001##
or the salts thereof, as well as the use thereof in the pharmaceutical, cosmetic or agrofood industry.
Vicinal primary diamines associated with metal and/or free radical chelation motifs, and active against carbonyl and oxidative stress, and use thereof
The invention relates to compounds of Formula I: ##STR00001##
or the salts thereof, as well as the use thereof in the pharmaceutical, cosmetic or agrofood industry.
Capture and release of acid gasses using tunable organic solvents with aminopyridine
A class of water lean, organic solvents that can bind with various acid gasses to form acid gas bound molecules having a high degree of intramolecular hydrogen bonding which enables their use as regenerable solvents for acid gas capture. Unlike the other devices described in the prior art, the present invention takes advantage of shortened distances between the portions of the molecule that form hydrogen bonds within the structures when loaded with an acid gas so as to create a molecule with a higher internal bonding affinity and a reduced proclivity for agglomeration with other molecules.
4-((6-(2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-2-HYDROXY-3-(5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL)PROPYL)PYRIDIN-3-YL)OXY)BENZONITRILE AND PROCESSES OF PREPARATION
Provided herein are methods for the preparation of 4-((6-(2-(2,4-difluorophenyl)-1, 1-difluoro-2-hydroxy-3-(5-mer-capto-1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile.
GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF
A compound has a guanidine skeleton that inhibits the protease activity of MALT1 and exerts a therapeutic or prophylactic effect on autoimmune disease such as psoriasis or allergic disease such as atopic dermatitis. The guanidine derivative is typified by the following formula or a pharmacologically acceptable salt thereof.
##STR00001##
GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF
A compound has a guanidine skeleton that inhibits the protease activity of MALT1 and exerts a therapeutic or prophylactic effect on autoimmune disease such as psoriasis or allergic disease such as atopic dermatitis. The guanidine derivative is typified by the following formula or a pharmacologically acceptable salt thereof.
##STR00001##
Therapeutic compounds as inhibitors of the orexin-1 receptor
The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.